Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition

Journal of Immunotherapy

Volumn 32, Issue 8, 2009, Pages 785-792

  Lindqvist, Camilla ^a   Sandin, Linda C ^a   Fransson, Moa ^a   Loskog, Angelica ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Apoptosis; CD107a; CD40L; FoxP3; Gene therapy; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DISSEMINATED CANCER; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; FEMALE; GENE TRANSFER; IMMUNOLOGICAL TOLERANCE; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CD40 LIGAND; CELL GROWTH PROCESSES; CYTOTOXICITY, IMMUNOLOGIC; GENE THERAPY; GENETIC VECTORS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MICE; MICE, INBRED C57BL; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 70349685209     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181acea69     Document Type: Article

References (26)

1. Linehan DC, Goedegebuure PS. CD25+CD4+ regulatory T-cells in cancer. Immunol Res. 2005;32:155-168.
2. Loskog A, Dzojic H, Vikman S et al. AdCD40L gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol. 2004;172:7200-7205.
3. Chade DC, Andrade PM, Borra RC, et al. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol. 2008;34:220-226.
4. Loskog A, Ninalga C, Hedlund T, et al. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim. 2005;39:384-393.
5. Loskog A, Todie; tterman TH. CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets. 2007;7:23-28.
6. Schodie; nbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
7. Loskog A, Bjorkland A, Brown MP, et al. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol. 2001;166:1093-1097.
8. Loskog ASI, Fransson ME, Todie; tterman TH. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res. 2005;11:8816-8821.
9. Summerhayes IC, Franks LM. Effectors of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst. 1979;62:1017-1023.
10. Grossman ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Human Gene Ther. 1997;8:1935-1943.
11. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Human Gene Ther. 1999;10:1375-1387.
12. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolerized T cells. Nat Immunol. 2000;1:311-316.
13. Halak BK, Maguire HC, Lattime EC. Tumor-induced interleukine- 10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 1999;59:911-917.
14. Mege J-L, Meghari S, Honstettre A, et al. The two faces of interleukin 10 in human infectious diseases. Lancet Inf Dis. 2006;6:557-569.
15. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 2007;8:457-462.
16. Banham AH. Cell-surface IL-7 receptor expression facilitates the puri.cation of FOXP3(+) regulatory T cells. TRENDS Immunol. 2006;27:541-544.
17. Georgopoulos NT, Steele LP, Thomson MJ, et al. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Di.er. 2006;13:1564-1576.
18. Grech AP, Amesbury M, Chan T, et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NFkappaB activation in mature B cells. Immunity. 2004;21: 629-642.
19. Hostager BS, Haxhinasto SA, Rowland SL, et al. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-de.cient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem. 2003;278:45382-45390.
20. Eliopoulos AG, Dawson CW, Mosialo G, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein- Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene. 1996;13:2243-2254.
21. Ghamande S, Hylander BL, O.azoglu E, et al. Recombinant CD40 ligand therapy has signi.cant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 2001;61:7556-7562.
22. Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001;7:691-703.
23. Tong AW, Seamour B, Chen J, et al. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma. 2000;36:543-558.
24. Loskog A, Todie; tterman TH, Bodie; hle A, et al. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modi.ed to express CD154. Cancer Gene Ther. 2002;9:846-853.
25. Dilloo D, Brown M, Roskrow M, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997;90: 1927-1933.
26. Kato K, Cantwell MJ, Sharma S, et al. Gene transfer of CD40- ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133-1141.